Abstract

This study aimed to illustrate the mechanism by which Shenmayizhi decoction (SMYZD) improves the learning memory of rats with vascular cognitive impairment (VCI). Fifty male and female Wistar rats of specific pathogen-free grade (SPF grade) were used to establish the model by the administration of a microsphere embolization. This was accomplished by injecting sterile, standardized, mass-produced microspheres of uniform particle size (100–200 µm in diameter) in a sodium alginate microsphere vascular embolic agent suspension to induce VCI. The VCI model was successfully established in 40 rats, including both male and female rats, and the rats were randomly divided into 4 groups of 10 rats each. The model group was administered an equal volume of distilled water. The donepezil group was administered 0.45 mg/kg/d donepezil, which is equivalent to the clinical dosage. The SMYZ-H group was administered 11.88 g/kg/d SMYZ, which is 4 times higher than the clinically equivalent dosage. The SMYZ-L group was administered 2.97 g/kg/d SMYZ, which is the clinically equivalent dosage. A sham-operated group was used as the control group and administered an equal volume of distilled water. The rats in the 4 groups were treated by gavage with equal volumes of liquid and the indicated concentration of drug diluted in distilled water for 8 consecutive weeks. Two months later, the Morris water maze (MWM) was used to evaluate the spatial memory of all the rats. Ultrastructural and ultrapathological changes in the capillaries of the cerebral cortex were observed by transmission electron microscopy. Furthermore, Western blot and RT-PCR analyses were used to assess the levels of platelet-derived growth factor receptor-β (PDGFR-β), neuron-glial antigen 2 (NG2), vascular endothelial growth factor A (VEGF-A), and angiopoietin 1 (Ang1) in the cerebral cortex of the rats. The results showed that SMYZD at concentrations of 11.88 g/kg/d and 2.97 g/kg/d (SMYZ-H and SMYZ-L) significantly shortened the escape latency (EL). In addition, SMYZ-H significantly prolonged the distance traveled and the time spent in the original platform quadrant by the rats with VCI. SMYZ-H significantly increased the NG2 and Ang1 protein expression levels and increased the PDGFR-β and Ang1 mRNA levels. These results demonstrated that Shenmayizhi decoction can improve the memory abilities of rats with VCI induced by multiple cerebral infarctions by preventing pericyte degeneration.

Highlights

  • Vascular cognitive impairment (VCI) is a type of cognitive disorder associated with cerebrovascular disease (CBVD) [1] and encompasses the full range of cognitive deficits from mild cognitive impairment to dementia. e etiology of VaD mainly includes two parts, namely, cerebrovascular disease and risk factors. e risk factors for vascular dementia include cerebrovascular disease, stroke, white matter ischemic lesions, advanced age, and low education level [2, 3]

  • We aimed to explore the relationship between cerebral microvascular pericyte degeneration and vascular cognitive impairment, the regulatory mechanism underlying the effects of Shenmayizhi decoction (SMYZD), and the correlation of SMYZD with cerebral microvascular pericytes

  • Fifty male and female specific pathogen-free grade (SPF grade) Wistar rats weighing 200–220 g were obtained from the Chinese Academy of Medical Science (license number: SCXK (Beijing) 2016–0006). e experiment was carried out after 7 days of adaptive feeding in a room where the temperature was controlled at 24°C∼26°C and the humidity was controlled at 40%∼70%. e animal model and experiment processes were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. is experiment was approved by the Committee on Ethics of Animal Experiments of Xiyuan Hospital of China Academy of Chinese Medical Sciences (No 2018XLC004-2)

Read more

Summary

Introduction

Vascular cognitive impairment (VCI) is a type of cognitive disorder associated with cerebrovascular disease (CBVD) [1] and encompasses the full range of cognitive deficits from mild cognitive impairment to dementia. e etiology of VaD mainly includes two parts, namely, cerebrovascular disease and risk factors. e risk factors for vascular dementia include cerebrovascular disease, stroke, white matter ischemic lesions, advanced age, and low education level [2, 3]. Vascular cognitive impairment (VCI) is a type of cognitive disorder associated with cerebrovascular disease (CBVD) [1] and encompasses the full range of cognitive deficits from mild cognitive impairment to dementia. E etiology of VaD mainly includes two parts, namely, cerebrovascular disease and risk factors. E risk factors for vascular dementia include cerebrovascular disease, stroke, white matter ischemic lesions, advanced age, and low education level [2, 3]. VCI is the second most common neuropathology associated with dementia, accounting for up to one-third of the population risk. VCI is still considered to be a type of dementia that can be prevented, and it may be reversible with early intervention. Ere is increasing awareness that targeting vascular risk may help prevent dementia. Exploring the pathogenesis of VCI will pave the way for the development of treatments that target the underlying diseaserelated processes

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call